Carboplatin-d4
(Synonyms: NSC 241240-d4) 目录号 : GC49286
卡铂-d4 (NSC 241240-d4) 是氘标记的卡铂。 Carboplatin (NSC 241240) 是一种 DNA 合成抑制剂，可与 DNA 结合，抑制复制和转录并诱导细胞死亡。 Carboplatin (NSC 241240) 是 CDDP 的衍生物，是一种有效的抗癌剂。
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Carboplatin-d4 is intended for use as an internal standard for the quantification of carboplatin by GC- or LC-MS. Carboplatin is a platinum-containing DNA-crosslinking agent.1 It induces the formation of DNA interstrand crosslinks and DNA-protein crosslinks when used at concentrations of 200 and 300 µM. It inhibits the proliferation of GLC-4 small cell lung carcinoma and A2780 and SKOV3 ovarian cancer cells (IC50s = 22.7, 0.5, and 10.2 µM, respectively).2,3 Carboplatin reduces tumor growth in an ADJ/PC6 murine plasmacytoma model (ED90 = 0.6 mg/kg, i.p.).4 Formulations containing carboplatin have been used in the treatment of ovarian cancer.
1.Micetich, K.C., Barnes, D., and Erickson, L.C.A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cellsCancer Res.45(9)4043-4047(1985) 2.Groen, H.J., Sleijfer, S., Meijer, C., et al.Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell linesBr. J. Cancer72(6)1406-1411(1995) 3.Al-Eisawi, Z., Beale, P., Chan, C., et al.Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour modelsJ. Ovarian Res.6(1)78(2013) 4.Kelland, L.R., Abel, G., McKeage, M.J., et al.Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): An orally active platinum drugCancer Res.53(11)2581-2586(1993)
| Cas No. | N/A | SDF | |
| 别名 | NSC 241240-d4 | ||
| Canonical SMILES | O=C([O-][Pt+2]1([NH3])[NH3])C2(C([2H])([2H])CC2([2H])[2H])C([O-]1)=O | ||
| 分子式 | C6H8D4N2O4Pt | 分子量 | 375.3 |
| 溶解度 | Methanol: slightly soluble,Water: slightly soluble | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6645 mL | 13.3227 mL | 26.6454 mL |
| 5 mM | 0.5329 mL | 2.6645 mL | 5.3291 mL |
| 10 mM | 0.2665 mL | 1.3323 mL | 2.6645 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quantification of intact carboplatin in human plasma ultrafitrates using hydrophilic interaction liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study
J Chromatogr B Analyt Technol Biomed Life Sci 2013 Feb 15;917-918:18-23.PMID:23348368DOI:10.1016/j.jchromb.2012.11.024
Carboplatin is a platinum agent that is used for treatment of non-small-cell lung cancer and ovarian cancer. A sensitive and selective analytical method for the quantification of carboplatin in human plasma ultrafiltrates using liquid chromatography-tandem mass spectrometry was developed. Human plasma ultrafiltrates were precipitated by acetonitrile containing Carboplatin-d4 as an internal standard and were further diluted with acetonitrile. Chromatographic separation was performed on a Accucore HILIC (50mm×2.1mm i.d., 2.6μm) column using mobile phase (acetonitrile-water-acetic acid=90:10:0.1, v/v/v) at the flow rate of 0.2mL/min. Detection was performed on electrospray ionization triple quadrupole tandem mass spectrometer using low-energy collision induced dissociation (CID-MS/MS) analysis operating in the selected reaction monitoring (SRM) scan mode. The lower limit of quantification for carboplatin was 0.025μg/mL. This method covered a linearity range of 0.025-50μg/mL. The intra-day precision and inter-day precision (R.S.D.) ranged from 1.5 to 4.3%, and the accuracy (R.E.) was within ±2.9%. The present method was applied to a clinical pharmacokinetic study of carboplatin in a cancer patient.